Role of tau in Alzheimer's dementia and other neurodegenerative diseases

Journal of Applied Biomedicine

Volumn 5, Issue 1, 2007, Pages 1-12

  Quadros, Amita ^a,b   Weeks, Ophelia Inez ^b   Ait Ghezala, Ghania ^a,b  

^a ROSKAMP INSTITUTE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Frontotemporal dementia; Parkinsonism; Pick's disease; Progressive supranuclear palsy; Tauopathies

Indexed keywords

ADENYLATE CYCLASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; ARGININE; ASPARAGINE; CASEIN KINASE IDELTA; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; GAMMA SECRETASE; GLYCINE; GLYCOGEN SYNTHASE KINASE 3; HISTIDINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHENYLALANINE; PRESENILIN 1; PRESENILIN 2; PROLINE; PROTEIN P35; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; THREONINE; VALINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CHROMOSOME 17; CORRELATION FUNCTION; DEGENERATIVE DISEASE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; MICROTUBULE ASSEMBLY; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSONISM; PATHOGENESIS; PICK PRESENILE DEMENTIA; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SENILE PLAQUE; TAUOPATHY;

EID: 33847699725     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.32725/jab.2007.001     Document Type: Review

References (88)

1. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K: Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer-disease. Proc. Natl. Acad. Sci. U.S.A. 91:5562-5566, 1994.
2. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J: Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453:260-264, 1999.
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631-639, 1992
4. Augustinack JC, Schneider A, Mandelkow EM Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103:26-35, 2002a.
5. Augustinack JC, Sanders JL, Tsai LH, Hyman BT: Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in preneurofibrillary tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 61:557-564, 2002b.
6. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8:711-715, 1999.
7. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E et al.: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916-919, 2006.
8. Berry RW, Quinn B, Johnson N, Cochran EJ, Ghoshal N, Binder LI: Pathological glial tau accumulations in neurodegenerative disease: review and case report. Neurochem. Int. 39:469-479, 2001.
9. Binder LI, Frankfurter A, Rebhun LI: The distribution of tau in the mammalian central - nervous system. J. Cell Biol. 101:1371-1378, 1985.
10. Brandt R, Hundelt M, Shahani N: Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 1739:331-354, 2005.
11. Bronner IF, Ter Meulen BC, Azmani A, Severijnen LA, Willemsen R, Kamphorst W, Ravid R, Heutink P, van Swieten JC: Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain 128:2645-2653, 2005.
12. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33:95-130, 2000.
13. Buee-Scherrer V, Goedert M: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett. 515:151-154, 2002.
14. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R et al.: Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59:1267-1272, 2002.
15. Butler M, Shelanski ML: Microheterogeneity of microtubule-associated tau proteins is due to differences in phosphorylation. J. Neurochem. 47:1517-1522, 1986.
16. Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen XH, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, et al.: Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann. Neurol. 41:277-281, 1997.
17. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K et al.: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q2l. Nature 442:920-924, 2006.
18. Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers I, Sacrens J, Pickut BA, Peeters K, van den Broeck M, Vennekens K, Claes S, Cruts M et al.: A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol. 55:617-626, 2004.
19. D'Souza I, Schellenberg GD: Regulation of tau isoform expression and dementia. Biochim. Biophys. Acta 1739:104-115, 2005.
20. Ferrer I, Blanco R, Carmona M, Puig B: Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/ calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural. Transm. 108:1397-1415, 2001.
21. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J: Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2:3-18, 2005.
22. Furukawa K, Wang Y, Yao PJ, Fu WM, Mattson MP, Itoyama Y, Onodera H, D'Souza I, Poorkaj PH, Bird TD, Schellenberg GD: Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J. Neurochem. 87:427-436, 2003.
23. Giaccone G, Rossi G, Farina L, Marcon G, Di Fede G, Catania M, Morbin M, Sacco L, Bugiani O, Tagliavini F: Familial frontotemporal dementia associated with the novel MAPT mutation T427M. J. Neurol. 252:1543-1545, 2005.
24. Goedert M, Jakes R: Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739:240-250, 2005.
25. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA: Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats differential expression of tau protein mRNAs in human brain. EMBO J. 8:393-399, 1989.
26. Gong CX, Grundke-Iqbal I, Iqbal K: Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61:765-772, 1994a.
27. Gong CX, Grundke-Iqbal I, Damuni Z, Iqbal K: Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett. 341:94-98, 1994b.
28. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Post-translational modifications of tau protein in Alzheimer's disease. J. Neural. Transm. 112:813-838, 2005.
29. Gotz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495, 2001
30. Gotz J, Ittner LM, Schonrock N: Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy? Med. J. Aust. 185:381-384, 2006
31. Grover A, DeTure M, Yen SH, Hutton M: Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci Lett. 323:33-36, 2002.
32. Haass C, De Strooper B: The presenilins in Alzheimer's disease-proteolysis holds the key. Science 286:916-919, 1999
33. Halliday GM, Song YJ, Lepar G, Brooks WS, Kwok JB, Kersaitis C, Gregory G, Shepherd CE, Rahimi F, Schofield PR, Kril JJ: Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann. Neurol. 57:139-143, 2005.
34. Hardy J, Selkoe DJ: Medicine - The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356, 2002
35. Hayashi S, Toyoshima Y, Hasegawa M, Umeda Y, Wakabayashi K, Tokiguchi S, Iwatsubo T, Takahashi H: Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann. Neurol. 51:525-530, 2002.
36. Henderson JM, Carpenter K, Cartwright H, Halliday GM: Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123:1410-1421, 2000.
37. Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, Trojanowski JQ, Lee VMY: Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35:433-446, 2002.
38. Hogg M, Grujic ZM, Baker M, Demirci S, Guillozet AL, Sweet AP, Herzog LL, Weintraub S, Mesulam MM, LaPointe NE, Gamblin TC, Berry RW et al.: The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol. 106:323-336, 2003.
39. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J et al.: Corticobasal degeneration and progressive supranuclear palsy share common tau haplotype. Neurology 56: 1702-1706, 2001.
40. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature.393:702-705, 1998.
41. Karenberg A: A long story starting with a short paper: Early history of Pick's disease. Fortschr. Neurol. Psychiatr. 69:545-550, 2001.
42. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Murphy MP, Baker M, Yu X, Duff K, Hardy J et al.: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:402-405, 2000.
43. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J et al.: Enhanced neurofibrillary degeneration in transgeni mice expressing mutant tau and APP. Science 293:1487-1491, 2001.
44. Lindwall G, Cole RD: Phosphorylation affects the ability of tau-protein to promote microtubule assembly. J. Biol. Chem. 259:5301-5305, 1984.
45. Lippa CF, Zhukareva V, Kawarai T, Uryu K, Shafiq M, Nee LE, Grafman J, Liang Y, St George-Hyslop PH, Trojanowski JQ, Lee VMY: Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Ann. Neurol. 48:850-858, 2000.
46. Litvan I, Hutton M: Clinical and genetic aspects of progressive supranuclear palsy. J. Geriatr. Psychiatry Neurol. 11: 107-114, 1998.
47. Mack TG, Dayanandan R, Van Slegtenhorst M, Whone A, Hutton M, Lovestone S, Anderton BH: Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. Neuroscience 108:701-712, 2001.
48. Mailliot C, Bussiere T, Hamdane M, Sergeant N, Caillet ML, Delacourte A, Buee L: Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities. Ann. N. Y. Acad Sci. 920:107-114, 2000.
49. Moller HJ, Graeber MB: The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur. Arch. Psychiatry Clin. Neurosci. 248:111-122, 1998.
50. Mori H: Frontotemporal dementia and frontotemporal degeneration - how to define? (In Japanese). Rinsho Shinkeigaka 44:872-874, 2004.
51. Morris HR, Gibb G, Katzenschlager R, Wood NW, Hanger DP, Strand C, Lashley T, Daniel SE, Lees AJ, Anderton BH, Revesz T: Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 125:969-975, 2002.
52. Morris HR, Osaki Y, Holton J, Lees AJ, Wood NW, Revesz T, Quinn N: Tau exon 10 + 16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology 61:102-104, 2003.
53. Murrell JR, Spillantini MG, Zolo P, Guazzelli M, Smith MJ, Hasegawa M, Redi F, Crowther RA, Pietrini P, Ghetti B, Goedert M: Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J. Neuropathol. Exp. Neurol. 58: 1207-1226, 1999.
54. Neumann M, Schulz-Schaeffer W, Crowther RA, Smith MJ, Spillantini MG, Goedert M, Kretzschmar HA: Pick's disease associated with the novel Tau gene mutation K369I. Ann. Neurol. 50:503-513, 2001.
55. Nicholl DJ, Greenstone MA, Clarke CE, Rizzu P, Crooks D, Crowe A, Trojanowski JQ, Lee VMY, Heutink P: An English kindred with a novel recessive tauopathy and respiratory failure. Ann. Neurol. 54:682-686, 2003.
56. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24:1063-1070, 2003.
57. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332, 2004.
58. Papasozomenos SC, Binder LI: Phosphorylation determines 2 distinct species of Tau in the central-nervous-system. Cell Motil, Cytoskeleton 8:210-226, 1987.
59. Paudel HK, Lew J, Ali Z, Wang JH: Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268:23512-23518, 1993.
60. Pei JJ, Braak E, Braak H, Grundke-Iqbal I., Iqbal K, Winblad B, Cowburn RF: Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis. 3:41-48, 2001.
61. Pickering-Brown S, Baker M, Yen SH, Liu WK, Hasegawa M, Cairns N, Lantos PL, Rossor M, lwatsubo T, Davies Y, Allsop D, Furlong R et al.: Pick's disease is associated with mutations in the tau gene. Ann. Neurol. 48:859-867, 2000.
62. Pickering-Brown SM, Baker M, Nonaka T, Ikeda K, Sharma S, Mackenzie J, Simpson SA, Moore JW, Snowden JS, de Silva R, Revesz T, Hasegawa M et al.: Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. Brain 127:1415-1426, 2004
63. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43:815-825, 1998.
64. Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, Koller WC, Bird TD, Trojanowski JQ, Lee VMY, Schellenberg GD: An (R)5(L) tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann. Neurol. 52:511-516, 2002.
65. Probst A, Tolnay M, Langui D, Goedert M, Spillantini MG: Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol. 92:588-596, 1996.
66. Puig B, Vinals F, Ferrer I: Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol. 107:185-189, 2004.
67. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH: Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem. 74:1587-1595, 2000.
68. Ridley RM, Baker HF, Windle CP, Cummings RM: Very long term studies of the seeding of beta-amyloidosis in primates. J. Neural. Transm. 113:1243-1251, 2006.
69. Rizzini C, Goedert M, Hodges JR, Smith MJ, Jakes R, Hills R, Xuereb JH, Crowther RA, Spillantini MG: Tau gene mutation K257T causes a tauopathy similar to Pick's disease. J. Neuropathol. Exp. Neurol. 59:990-1001, 2000.
70. Ros R, Thobois S, Streichenberger N, Kopp N, Sanchez MP, Perez M, Hoenicha J, Avila J, Honnorat J, de Yebenes JG: A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch. Neurol. 62:1444-1450, 2005a.
71. Ros R, Gomez Garre P, Hirano M, Tai YF, Ampuero I, Vidal L, Rojo A, Fontan A, Vazquez A, Fanjul S, Hernandez J, Cantarero S et al.: Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann. Neurol. 57:634-641, 2005b.
72. Rosso SM, van Herpen E, Deelen W, Kamphorst W, Severijnen LA, Willemsen R, Ravid R, Niermeijer MF, Dooijes D, Smith MJ, Goedert M, Heutink P et al.: A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Ann. Neurol. 51:373-376, 2002.
73. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481, 2005
74. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL: Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol. Aging 21:503-510, 2000.
75. Sergeant N, Delacourte A, Buee L: Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta 1739:179-97, 2005
76. Shepherd CE, Gregory GC, Vickers JC, Brooks WS, Kwok JBJ, Schofield PR, Kril JJ, Halliday GM: Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol. Dis. 15:115-119, 2004.
77. Spillantini MG, Goedert M: Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21:428-433, 1998.
78. Stanford PM, Halliday GM, Brooks WS, Kwok JBJ, Storey CE, Creasey H, Morris JGL, Fulham MJ, Schofield PR: Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. Expansion of the disease phenotype caused by tau gene mutations. Brain 123:880-893, 2000.
79. Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10:333-359, 1964.
80. Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, Ichikawa M, Yamaguchi H, Takashima A: Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22:133-141, 2002.
81. Tomizawa K, Omori A, Ohtake A, Sato K, Takahashi M: Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. FEBS Lett. 492:221-227, 2001.
82. van Slegtenhorst M, Lewis J, Hutton M: The molecular genetics of the tauopathies. Exp. Gerontol. 35:461-471, 2000.
83. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW: A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U.S.A. 72:1858-1862, 1975.
84. Wilhelmus MM, Otte-Holler I, Davis J, Van Nostrand WE, de Waal RMW, Verbeek MM: Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J. Neurosci. 25:3621-3627, 2005.
85. Yen SH, Hutton M, DeTure M, Ko LW, Nacharaju P: Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17. Brain Pathol. 9:695-705, 1999.
86. Yoshida H, Crowther RA, Goedert M: Functional effects of tau gene mutations Delta N296 and N296H. J. Neurochem. 80:548-551, 2002.
87. Zarranz JJ, Ferrer I, Lezcano E, Forcadas MI, Eizaguirre B, Atares B, Puig B, Gomez-Esteban JC, Fernandez-Maiztegui C, Rouco I, Perez-Concha T, Fernandez M et al.: A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology 64:1578-1585, 2005.
88. Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K, Grossman M, Miller BL, Hulette CM, Feinstein SC, Trojanowski JQ, Lee VMY: Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann. Neurol. 51:730-739, 2002.